Business Wire

MEDSCAPE

Share
Medscape Global Launches Innovative Programmatic Offering Setting a New Standard in Targeted HCP Engagement in the United Kingdom, European Union and Canada

Medscape, the leading provider of healthcare information globally, and PulsePoint, which offers a marketing technology platform, are integrating their capabilities to introduce Medscape Extend. For the first time ever, this innovative solution empowers marketers to accurately reach and message verified healthcare professionals (HCPs) across the internet in the UK, EU, and Canada. With Medscape Extend, Medscape has integrated its highly engaged and authenticated HCP membership with PulsePoint's programmatic targeting capabilities into a single platform that enables the delivery of advertising to HCPs across all digital media touchpoints.

“The global pharma media industry is in a period of positive transformation, with publishers, agencies and clients pushing for increasingly intelligent approaches to prescription brand challenges. Medscape Extend is a brilliant addition to this and opens the door to creative media campaigns both on and off the Medscape Professional Network,” said Richard Springham, Managing Director, Initiative Health. “The ability to target verified HCPs in a multi-dimensional manner across their entire media journey is a key facet of modern HCP media campaigns. The team at Medscape have been able to build this in a connected, compliant, and scalable way. I’m excited to see how planners across the industry use Medscape Extend creatively in campaigns.”

In the ever-evolving landscape of pharmaceutical marketing, reaching healthcare professionals with targeted and relevant content wherever they engage is crucial. One powerful tool in the arsenal of global pharma marketers remains messaging HCPs on endemic sites like the Medscape Everywhere network. However, with Medscape Extend, marketers can now extend this marketing strategy across the open internet and in a manner that is fully compliant against the necessary European General Data Protection Regulation (GDPR) consent.

“With this launch, we’re excited to continue delivering the market high quality audiences, with scale, transparency, and real-time optimization. There's a huge upside for advertisers who are looking to reach healthcare professionals in Europe and Canada,” said Jeremy Schneider, Group General Manager of WebMD Global. “Medscape Extend represents our commitment to innovation in advertising. As technology has evolved and data capabilities have gotten more precise, advertisers are demanding greater targeting sophistication and automated technologies in addition to the value of direct media.”

Key Benefits for Pharma Marketers:

  • Unrivaled reach: Greater reach, scale and opportunity to accurately engage HCPs throughout their journey starting on Medscape, and across the open Internet via PulsePoint’s technology
  • Unprecedented insights: Enhanced signals from Medscape 1st party HCP profiles combined with PulsePoint contextual data
  • GDPR Compliance through Medscape's Verification Process: Active opt-in 1st party consent data from Medscape’s Global Network properties

Initially, Medscape Extend will be used to deliver relevant unbranded content to healthcare professionals in the United Kingdom, European Union and Canada. As part of WebMD Health Corporation, a Internet Brands company, Medscape and PulsePoint already work together in the U.S. to deliver similar healthcare professional digital marketing solutions.

About Medscape

Medscape is the leading source of clinical news, health information, and point-of-care tools for health care professionals. Medscape offers specialists, primary care physicians, and other health professionals the most robust and integrated medical information and educational tools. Medscape Education (medscape.org) is the leading destination for continuous professional development, consisting of more than 30 specialty-focused destinations offering thousands of free CME and CE courses and other educational programs for physicians, nurses, and other health care professionals.

Both Medscape and Medscape Education are part of WebMD Health Corp., an Internet Brands company, which is part of the KKR portfolio.

About PulsePoint

PulsePoint is a leading technology company that uses real-world data in real time to optimize campaign performance and revolutionize health decision-making. Leveraging proprietary datasets and methodology, PulsePoint targets healthcare professionals and patients with an unprecedented level of accuracy—delivering unparalleled results to the clients we serve. The company is also part of Internet Brands. For more information, visit pulsepoint.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240214448771/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Thunder Bridge Capital Partners IV, Inc. and Coincheck Group N.V. Announce Closing of Business Combination10.12.2024 23:52:00 CET | Press release

Coincheck Group N.V. ordinary shares and warrants to begin trading on Nasdaq on December 11, 2024 as “CNCK” and “CNCKW,” respectively. Coincheck Group N.V. (“Coincheck”), a Dutch public limited liability company and a holding company of a cryptocurrency trading service company, and Thunder Bridge Capital Partners IV, Inc. (Nasdaq: THCP, THCPU & THCPW) (“Thunder Bridge IV”), a special purpose acquisition company, announced today the consummation of their previously announced business combination. As a result, the ordinary shares and warrants of Coincheck will commence trading on Nasdaq on December 11, 2024 under the new ticker symbols “CNCK” and “CNCKW,” respectively. The business combination was approved at a special meeting of the shareholders of Thunder Bridge IV on December 5, 2024. “The completion of our business combination with Thunder Bridge IV marks an extraordinary milestone for Coincheck,” said Oki Matsumoto, Representative Executive Officer and Chairman of Monex Group, Inc.,

IFF Names Michael DeVeau Chief Financial Officer10.12.2024 22:15:00 CET | Press release

DeVeau has served in senior global financial leadership roles across the organization during his 15-year IFF tenure, most recently as SVP, Corporate Finance and Investor Relations IFF (NYSE: IFF) today announced that Michael DeVeau—currently Senior Vice President, Corporate Finance and Investor Relations at IFF—has been named the company’s Executive Vice President and Chief Financial Officer, effective Jan. 1, 2025. DeVeau will succeed current CFO and Business Transformation Officer Glenn Richter, whose previously announced planned retirement will take effect at the end of 2024. “We could not be more pleased than naming Mike as our CFO,” said Erik Fyrwald, IFF CEO. “Mike is a trusted, experienced executive at IFF and has been a pivotal leader across our company’s global finance functions over the last 15 years. We conducted a thorough evaluation process, and I am proud that we identified the right leader with decades of industry experience and longstanding relationships with the invest

Lattice Advances Low Power FPGA Leadership with New Small and Mid-range FPGA Offerings10.12.2024 19:00:00 CET | Press release

‒ Introduces Lattice Nexus 2 next-gen small FPGA platform, extends mid-range portfolio with Lattice Avant 30 and Avant 50 devices, and enhances capabilities of application-specific solution stacks and design software tools ‒ Today, at Lattice Developers Conference 2024, Lattice Semiconductor (NASDAQ: LSCC) expanded its edge to cloud FPGA innovation leadership with the launch of exciting new hardware and software solutions. The new Lattice Nexus™ 2 next-gen small FPGA platform and the first device family based on the platform, Lattice Certus™-N2 general purpose FPGAs, offer advanced connectivity, optimized power and performance, and class-leading security. Lattice also announced new mid-range FPGA device capacity options – Lattice Avant™ 30 and Avant™ 50 – and new versions of Lattice design software tools and application-specific solution stacks to help accelerate customer time-to-market. “At Lattice, we are proud to lead technological advancements in low power, small form factor FPGAs,

nShift: Growing Ecoms Urged to Stop “Leaving Money on the Table” in 202510.12.2024 17:01:00 CET | Press release

nShift releases five ways that deliveries can solve business problems Small and medium-sized ecommerce businesses fear they are leaving money on the table by failing to optimize their processes, learn from data analytics and improve their customer experience. Experts at nShift are calling on growing and ambitious ecom companies to make 2025 the year they start using the delivery process to maximize revenue and solve business challenges. Smaller ecommerce businesses are better placed than their larger competitors to respond quickly to shifting customer expectations. But many may be missing opportunities to spot these trends. One in five small businesses does not actively track ecommerce analytics.1 nShift, the global leader in delivery and experience management, has identified five ways that the delivery process can help grow revenue, boost loyalty and solve business problems: Increase conversions at checkout – some 70% of shoppers confess to abandoning online shopping carts.2 nShift da

Incyte Late-Breaking Tafasitamab (Monjuvi®) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular Lymphoma10.12.2024 16:30:00 CET | Press release

The pivotal Phase 3 inMIND trial met its primary endpoint of progression-free survival (PFS) and key secondary endpoints in patients with relapsed or refractory follicular lymphoma (FL) treated with tafasitamab (Monjuvi®) in combination with lenalidomide and rituximabPositive data featured in a late-breaking oral presentation at the 2024 American Society of Hematology (ASH) Annual Meeting support the planned U.S. filing of a supplemental Biologics License Application (sBLA) for tafasitamab in FL by year-end 2024Incyte to host virtual analyst and investor event on Thursday, December 12, 2024, from 4:00-5:00 p.m. ET to discuss key data presented at ASH Incyte (Nasdaq:INCY) today announced additional results from the pivotal Phase 3 inMIND trial evaluating treatment with tafasitamab (Monjuvi®), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, in combination with lenalidomide and rituximab compared with placebo plus lenalidomide and rituximab in patients with relapsed

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye